Development of bioreductive markers for tumour hypoxia.

Hypoxic cells in tumours can be identified by exposing them to an immunologically identifiable 2-nitroimidazole (NITP) with a theophylline substituent which becomes bioreductively metabolised and binds to cellular macromolecules in the absence of oxygen. A range of monoclonal and polyclonal antibodies raised against theophylline or caffeine can identify cells containing bound adducts of NITP, in some cases with higher specificity than the standard product used. An alternative approach utilizes the very high specificity of FITC-avidin as a reagent to detect metabolic binding of a 2-nitroimidazole with a biotinylated side-chain (NIB), with the advantage of a single-step staining protocol. Both proliferating and hypoxic cell populations within tumours can be identified by simultaneous staining for incorporation of NITP and BrdUrd and this has shown that some cells incorporate both markers, suggesting that there is some overlap between the proliferating and hypoxic cell compartments.